Webb3 jan. 2024 · Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange PRNewswire 4:30 PM -- December 5, 2024 -- Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed … Webb12 apr. 2024 · Protalix Biotherapeutics Inc (PLX) stock is higher by 6.17% while the S&P 500 has fallen -0.09% as of 11:05 AM on Wednesday, Apr 12. PLX has risen $0.14 from the previous closing price of $2.35 on volume of 1,981,573 shares.
Protalix Biotherapeutics Inc (PLX) Stock Price & News - Google
Webb12 sep. 2013 · This letter is being delivered to you in connection with a proposed Purchase Agreement (the “Purchase Agreement”) between Protalix BioTherapeutics, Inc., a Florida corporation (the “Company”), and you as representative of a group of Initial Purchasers named therein, relating to an offering of Convertible Notes due 2024, which will be … Webb24 sep. 2024 · About Protalix Biotherapeutics' Clinical Programs in Fabry Disease The BALANCE Study is a 24-month, randomized, double blind, active control study of PRX‑102 (pegunigalsidase alfa) in Fabry ... mp1300 ドライバ
Protalix BioTherapeutics - PLX - Stock Price Today - Zacks
Webb12 apr. 2024 · Protalix BioTherapeutics Inc. (PLX) currently has a stock price of $2.50. The stock saw a sharp increase in the last trading session, hitting a high of $2.35 after opening at $2.30. The lowest recorded price for the day was $2.27 before it closed at $2.35. The stock market performance of Protalix BioTherapeutics Inc. has been very steady. Webb12 apr. 2024 · Protalix Biotherapeutics Inc (PLX) stock is higher by 6.17% while the S&P 500 has fallen -0.09% as of 11:05 AM on Wednesday, Apr 12. PLX has risen $0.14 from … WebbProtalix BioTherapeutics Inc是一家生物制药公司，专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。它已经开发出用于治疗戈谢病的taliglucerase alfa。该公司的产品还用于治疗法布里病和囊性纤维化等疾病。 mp1200 シャフト メーカー